NCT06696261招募中3 期
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled Phase III Clinical Trial on the Efficacy and Safety of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome (Intermingled Cold and Heat).
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 342
- 试验地点
- 18
- 主要终点
- Postprandial distress syndrome response rate
研究概览
简要总结
The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are:
- Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo.
- Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome.
- Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 65 years old (including boundary value), gender is not limited;
- •meet the diagnostic criteria for postprandial distress syndrome (Rome IV.);
- •Meet the syndrome differentiation standards of Traditional Chinese Medicine for cold and heat miscellaneous syndromes;
- •NRS score of at least one symptom of postprandial distress syndrome (postprandial fullness, discomfort, early satiety) in the screening period and baseline period≥ 4 points; and did not have moderate/severe epigastric pain syndrome (mid-epigastric burning sensation and mid-upper quadrant pain both < 4 points);
- •Those who did not have organic abnormal changes in the results of gastroscopy (including no abnormalities in gastroscopy, chronic non-atrophic gastritis/chronic superficial gastritis with erythema grade I and/or erosion that was flat and only grade I);
- •Negative Helicobacter pylori test in 13C/14C breath test during the screening period;
- •Voluntarily participate in clinical trials, sign informed consent, and understand and comply with research procedures.
排除标准
- •Those who have undergone Helicobacter pylori eradication treatment within 6 months before screening;
- •Gastric mucosal erythema grade II or above, erosion is bulge or grade II or above, or accompanied by bleeding, bile reflux, ≥ 3 inflammatory polyps and other manifestations, or combined with pathological diagnosis of chronic atrophic gastritis, hyperplastic polyps, glandular polyps, etc.; or those who have been clearly diagnosed with dyspepsia caused by organic diseases of the digestive system, such as digestive tract tumors, hepatobiliary and pancreatic diseases, inflammatory bowel diseases, etc.; or those who have other diseases that affect the evaluation of dyspepsia-related symptoms in the past, such as reflux esophagitis, peptic ulcer, gastrointestinal bleeding, intestinal obstruction, etc.;
- •Those who have been diagnosed with systemic diseases that seriously affect the function of the digestive tract, such as hyperthyroidism or hypothyroidism, diabetes, chronic renal insufficiency, connective tissue diseases, etc.;
- •Patients with severe cardiovascular and cerebrovascular, liver, lung, kidney, blood or systemic diseases that affect their survival; or patients with severe mental illness in the past, such as moderate or severe depression/anxiety/bipolar disorder, etc.;
- •Those who have a history of major abdominal surgery in the past, which may affect gastrointestinal function (except for appendectomy, cesarean section, endoscopic colon polyp resection and other surgeries that do not affect digestive function);
- •Patients with abnormal liver function (ALT or AST >1.5 times the upper limit of normal) or abnormal renal function test (Cr> upper limit of normal);
- •Glycosylated hemoglobin ≥ 6.5% or fasting blood glucose ≥7mmol/L during the screening period;
- •Use of drugs or treatments that may have an impact on the effectiveness assessment of the trial drug within 2 weeks before screening (such as acid/antacids, gastrointestinal motility drugs, digestive enzymes, gastric mucosal protectors, antiemetics, antispasmodics, macrolide antimicrobials, azole antifungals, non-steroidal anti-inflammatory drugs, glucocorticoids, anti-anxiety and depressants, analgesics, sedatives; as well as traditional Chinese medicine decoctions, proprietary Chinese medicines and acupuncture treatments for the treatment of functional dyspepsia, etc.);
- •Pregnant and lactating women, who have a birth plan within one month after enrollment and the end of the trial;
- •Those who suspect or have a history of alcohol or drug abuse;
- •Participated in other clinical trials within 1 month before screening;
- •Those who are suspected or known to be allergic to the ingredients of this medicine;
- •According to the judgment of the investigator, it is not suitable to participate in this study.
研究组 & 干预措施
Lianxiaxiaopi Granules
Experimental
干预措施: Lianxiaxiaopi Granules (Drug)
a simulated agent of Lianxiaxiaopi Granules
Placebo Comparator
干预措施: a simulated agent of Lianxiaxiaopi Granules (Drug)
结局指标
主要结局
Postprandial distress syndrome response rate
时间窗: The end of Week 8
Postprandial Distress Syndrome Response, the number of weeks in which the subject responded to the postprandial distress syndrome was greater than 50% of the weeks throughout the treatment period. Response week, if the two symptoms of postprandial fullness and discomfort and early satiety decreased by ≥50% compared with the baseline per week, the response week was calculated by the diary card score.
次要结局
- postprandial distress syndrome score change from baseline(The end of Week 8)
- single symptom response rate(The end of Week 8)
- the change value of single symptom score from baseline(The end of Week 8)
- the change from baseline in epigstric pain syndrome score(The end of Week 8)
- epigastric pain syndrome response rate(The end of Week 8)
- the change from baseline in the total score of TCM(The end of Week 8)
- the change value of TCM single symptom score from baseline(The end of Week 8)
- TCM syndrome integral effective rate(The end of Week 8)
- the grade change of TCM single symptom from baseline(The end of Week 8)
- the proportion of subjects with sustained remission and no exacerbation of single symptoms at 12W compared with 8W(The end of Week 12)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
不适用
Study of Effects of YisuiShengxueGranules on ThalassemiaThalassemiaNCT01549080Guang'anmen Hospital of China Academy of Chinese Medical Sciences2
招募中
3 期
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and PlaceboAnkylosing SpondylitisNCT06000956Tasly Pharmaceutical Group Co., Ltd408
进行中（未招募）
2 期
Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous UlcersHealthyNCT06429566Zhejiang Echon Biopharm Limited120
进行中（未招募）
2 期
A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)Hyperplasia of BreastNCT04229706Tasly Pharmaceutical Group Co., Ltd180
Unknown
2 期
A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic RetinopathyModerately Severe to Severe NPDRNCT03258242Chengdu Kanghong Pharmaceutical Co., Ltd.198